Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
144 hedge funds and large institutions have $353M invested in Intercept Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 60 increasing their positions, 40 reducing their positions, and 31 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 40
11% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $13.3M
8% less funds holding
Funds holding: 156 → 144 (-12)
12% less capital invested
Capital invested by funds: $402M → $353M (-$49M)
35% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.2M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$6.32M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$5.46M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.6M |
| 3 |
Two Sigma Investments
New York
|
-$4.57M |
| 4 |
Jane Street
New York
|
-$4.11M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.97M |
ICPT Hedge Fund Activity: Q4 2022 in Review
144 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2022, worth a combined $353M — down 12% from $402M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ICPT and 20 opened new positions — a net loss of 11 holders — while 40 trimmed existing stakes and 60 added.
The largest buyer was Vanguard Group, adding an estimated $13.2M. The largest seller was Point72 Asset Management, cutting an estimated $19.7M.
- 144 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2022, down from 156 in Q3 2022.
- Funds reported $353M of Intercept Pharmaceuticals, Inc. stock for Q4 2022, down 12% quarter-over-quarter.
- 20 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2022 and 31 closed out, a net change of -11 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2022 was Vanguard Group, an estimated $13.2M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q4 2022 was Point72 Asset Management, an estimated $19.7M sold.
Based on aggregated 13F filings for Q4 2022.